Dr. Reddy’s API plant in Hyderabad gets VAI classification from U.S. FDA
The Hindu
Dr. Reddy's Laboratories API facility in Hyderabad classified as VAI by U.S. FDA after inspection.
An active pharmaceutical ingredients (API) manufacturing facility of Dr. Reddy’s Laboratories in Hyderabad inspected last year by the United States Food and Drug Administration (U.S. FDA) has since been classified as Voluntary Action Indicated (VAI) by the agency.
“The U.S. FDA has classified the inspection as VAI and concluded that the inspection is closed...,” the generic drugmaker on Tuesday (February 25, 2025) said in an update to the stock exchanges on the inspection of the API manufacturing facility (CTO-2) in Bollaram, Hyderabad.
The U.S. FDA had conducted the GMP inspection from November 13-19 and issued a Form 483 with seven observations to the facility.

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












